A Phase 1 interventional study of Placebo and BLN-481 in Healthy Volunteers (no Disease Condition Under Study), sponsored by Beeline Medicines Corporation. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Beeline Medicines Corporation · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 1 first-in-human study will evaluate BLN-481 in healthy adults. Participants will receive BLN-481 or placebo. Part 1 evaluates single ascending intravenous (IV) doses (SAD) and optional subcutaneous (SC) doses. Part 2 evaluates multiple ascending subcutaneous doses (MAD). The main purpose is to assess safety and tolerability. The study will also evaluate how BLN-481 moves through the body, whether anti-drug antibodies (ANA) develop, and pharmacodynamic (PD) effects.
BLN-481 is a monoclonal allosteric blocking antibody targeting IL-18 receptor beta (IL-18Rβ). The study is randomized, double-blind, placebo-controlled, and uses sentinel dosing in each cohort. Part 1 includes sequential single-dose cohorts; Part 2 includes sequential multiple-dose cohorts administered every 2 (Q2W) or 4 (Q4W) weeks for three total doses. Dose escalation decisions will be based on review of available safety, tolerability, and pharmacokinetic (PK) data by the Dose Escalation Committee. Approximately 104 healthy adult participants are planned.
Beeline Medicines Corporation is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 (SAD): Single IV doses in Cohorts 1A-1E at planned doses of 10, 30, 100, 300, and 900 mg. Optional Cohort 1X may receive a single IV or SC dose; optional Cohorts 1Y and 1Z may receive a single SC dose, with dose levels to be determined. Each Part 1 cohort includes up to 8 participants randomized 6:2 to BLN-481: placebo. Part 2 (MAD): SC dosing in Cohort 2A at 50 mg Q2W, Cohort 2B at 150 mg Q2W, and Cohort 2C at 450 mg Q2W or Q4W, for 3 total doses. Optional Cohort 2D may receive a dose to be determined Q2W or Q4W for 3 total doses. Each Part 2 cohort includes up to 10 participants randomized 8:2 to BLN-481: placebo.
Drug: BLN-481
Matching placebo is administered by the same route and on the same schedule as the assigned BLN-481 cohort. Part 1 placebo is administered as a single IV infusion or SC injection. Part 2 placebo is administered SC Q2W or Q4W for 3 total doses. Each cohort uses blinded sentinel dosing: 1 participant assigned to BLN-481 and 1 participant assigned to placebo are dosed first before the remaining cohort participants.
Drug: Placebo
Matching placebo is administered by the same route and on the same schedule as the assigned BLN-481 cohort. Part 1 placebo is administered as a single IV infusion or SC injection. Part 2 placebo is administered SC Q2W or Q4W for 3 total doses. Each cohort uses blinded sentinel dosing: 1 participant assigned to BLN-481 and 1 participant assigned to placebo are dosed first before the remaining cohort participants.
Also known as: Placebo for BLN-481
Part 1 (SAD): Single IV doses in Cohorts 1A-1E at planned doses of 10, 30, 100, 300, and 900 mg. Optional Cohort 1X may receive a single IV or SC dose; optional Cohorts 1Y and 1Z may receive a single SC dose, with dose levels to be determined. Each Part 1 cohort includes up to 8 participants randomized 6:2 to BLN-481: placebo. Part 2 (MAD): SC dosing in Cohort 2A at 50 mg Q2W, Cohort 2B at 150 mg Q2W, and Cohort 2C at 450 mg Q2W or Q4W, for 3 total doses. Optional Cohort 2D may receive a dose to be determined Q2W or Q4W for 3 total doses. Each Part 2 cohort includes up to 10 participants randomized 8:2 to BLN-481: placebo.
Participant incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Summary of TEAEs and SAEs
Time frame: Up to 24 weeks
Clinically significant abnormalities in safety laboratory tests
Number of participants with clinically significant abnormalities in protocol-specified clinical laboratory assessments, including hematology, coagulation, chemistry, and urinalysis.
Time frame: Up to approximately 20 weeks
Clinically significant changes in spirometry for the 900mg IV Cohort in Part 1 (FEV1)
Change from baseline in FEV1 measured by spirometry in participants in the highest planned dose cohort (900 mg IV). FEV1 is normalized using the standards specified in the protocol.
Time frame: Baseline through Day 92 (approximately 13 weeks)
Clinically significant abnormalities in Vital Signs
Number of participants with clinically significant abnormalities in protocol-specified vital sign assessments, including blood pressure, heart rate, respiratory rate, body temperature, and pulse oximetry.
Time frame: Up to approximately 20 weeks
Clinically Significant Abnormalities in 12-Lead ECG QTcF Interval
Number of participants with clinically significant abnormalities in QT interval corrected for heart rate using Fridericia's formula (QTcF), as assessed by 12-lead ECG.
Time frame: Up to approximately 20 weeks
Clinically significant abnormalities on Physical Examination
Number of participants with clinically significant abnormalities identified during protocol-specified physical examinations. Complete physical examinations include assessment of the head, eyes, ears, nose, and throat (HEENT); neck; chest; lungs; abdomen; musculoskeletal, neurological, dermatological, cardiovascular, and peripheral vascular systems; and any areas of note identified during the daily review of adverse events. Targeted physical examinations are symptom-directed.
Time frame: Up to approximately 20 weeks
Clinically significant changes in spirometry from Baseline in Forced Vital Capacity (FVC) in the 900 mg IV Cohort
Change from baseline in FVC measured by spirometry in participants in the highest planned dose cohort (900 mg IV).
Time frame: Baseline through Day 92 (approximately 13 weeks)
Clinically significant changes in spirometry from Baseline in FEV1/FVC Ratio in the 900 mg IV Cohort
Change from baseline in the ratio of FEV1 to FVC measured by spirometry in participants in the highest planned dose cohort (900 mg IV).
Time frame: Baseline through Day 92 (approximately 13 weeks)
Clinically significant changes in spirometry from Baseline in Forced Expiratory Flow at 25% to 75% of FVC (FEF25-75%) in the 900 mg IV Cohort
Change from baseline in FEF25-75% measured by spirometry in participants in the highest planned dose cohort (900 mg IV).
Time frame: Baseline through Day 92 (approximately 13 weeks)
Part 1 serum pharmacokinetic parameters (Cmax) of BLN-481
Maximum observed serum concentration of BLN-481.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters (Tmax) of BLN-481
Time of maximum observed serum concentration of BLN-481.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters [AUC(0-T)] of BLN-481
Area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters [AUC(INF)] of BLN-481
Area under the serum concentration-time curve from time 0 extrapolated to infinite time.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters (T-HALF) of BLN-481
Terminal elimination half-life of BLN-481.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters Total Body Clearance (CLT) of BLN-481
Total body clearance of BLN-481 following intravenous administration.
Time frame: Up to 13 Weeks
Incidence of anti-drug antibodies (ADA) to BLN-481
Summary of ADA incidence by treatment arm and study part.
Time frame: Up to approximately 20 weeks
Part 1 serum pharmacokinetic parameters T(CLT/F) of BLN-481
Apparent total body clearance of BLN-481 following subcutaneous administration.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters (Vz) of BLN-481
Volume of distribution of the terminal phase of BLN-481 following intravenous administration.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters (Vz/F) of BLN-481
Apparent volume of distribution of the terminal phase of BLN-481 following subcutaneous administration.
Time frame: Up to 13 weeks
Part 1 serum pharmacokinetic parameters Absolute Bioavailability of BLN-481 Following Subcutaneous Administration
Absolute bioavailability of BLN-481 following a single subcutaneous administration.
Time frame: Up to 13 weeks
Part 2 serum pharmacokinetic parameters (Cmax) of BLN-481
Time of maximum observed serum concentration of BLN-481.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters (Tmax) of BLN-481
Time of maximum observed serum concentration of BLN-481.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters [AUC(TAU)] of BLN-481
Area under the serum concentration-time curve within a dosing interval.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters (Ctrough) of BLN-481
Trough observed serum concentration of BLN-481.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters (T-HALF) of BLN-481
Terminal elimination half-life of BLN-481.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters (AI_AUC) of BLN-481
Ratio of AUC(TAU) after the third dose to AUC(TAU) after the first dose.
Time frame: Up to 20 weeks
Part 2 serum pharmacokinetic parameters (AI_Cmax) of BLN-481
Ratio of Cmax after the third dose to Cmax after the first dose.
Time frame: Up to 20 weeks
Plan to share: No — Individual participate data will not be shared as this phase 1 study is explicitly designed to evaluate the safety, tolerability, and initial pharmacokinetics. The Sponsor intends to report study results in aggregate form, as applicable.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beeline Medicines Corporation